- MEP Lola Sánchez questions the European Commission: EU's position on the UN High-Level Panel on Access to Medicines at WIPO
- WTO TRIPS Council: Brazilian submission on Ecommerce and Copyright
- All 12 Zhang/Broad Institute CRISPR patents declare US funding and rights in inventions
- KEI Comments filed in USTR Special 301 Review
- WTO Trade Policy Review: Members question the United States on compulsory licensing, Bayh-Dole, UNHLP & Section 337
- EB140: WHO adopts decision on terms of reference for overall programme review of the GSPOA (31 Jan 2017)
- EB140 heats up during discussions of proposed changes to resolution on TOR of Overall Programme Review of GSPOA
- Feb 24, 2017 - U.S. History, Experiences, and Prospects of Compulsory Licensing of Medical Patents
- Chilean Cámara de Diputados votes overwhelmingly to advance compulsory licensing of drug patents.
- EB140: Statement of India on the Report of the United Nations High-Level Panel on Access to Medicines
If you are unable to attend the event but would like to follow it remotely, please follow the link above.
On Friday, February 24, 2017, KEI will host a meeting exploring compulsory licensing in the United States.
Title: History, Experiences, and Prospects of Compulsory Licensing on Medical Patents in the United States
Date: Friday February 24, 2017
Location: Kaiser Permanente Center for Total Health
MEP Lola Sánchez questions the European Commission: EU's position on the UN High-Level Panel on Access to Medicines at WIPOSubmitted by thiru on 22. February 2017 - 5:34
On 2 February 2017, MEP Lola Sánchez Caldentey (Podemos, Spain) tabled a series of written questions to the European Commission on the positions taken by the European Union at the World Intellectual Property Organization on 14 December 2016 in relation to the United Nations High-Level Panel on Access to Medicines (UN HLP)
In December 2016, Brazil submitted a proposal to the World Trade Organization entitled, ELECTRONIC COMMERCE AND COPYRIGHT (JOB/GC/113, JOB/IP/19), intended for circulation at the WTO's General Council and the TRIPS Council. This paper will be discussed at the next session of the TRIPS Council under agenda item 13, "Work Programme on Electronic Commerce" (1-2 March 2017).
February 15, 2017, the USPTO ruled that 12 genome-editing CRISPR-Cas9 patents and one patent application assigned to the Broad Institute of Harvard and MIT did not interfere with a patent application from scientists at the University of California. A copy of the ruling is available here.
Following the ruling by the USPTO that the Broad Institute and the University of California both issued statements, as did several firms with an interest in the dispute.
On February 9, 2017, KEI filed written comments to the Office of the United States Trade Representative's Special 301 Review process.
The Special 301 Review is an annual process carried out by the USTR to, "to identify countries that deny adequate and effective protection of intellectual property rights (IPR) or deny fair and equitable market access to U.S. persons who rely on intellectual property protection."
WTO Trade Policy Review: Members question the United States on compulsory licensing, Bayh-Dole, UNHLP & Section 337Submitted by thiru on 7. February 2017 - 6:07
In December 2016, during the twilight of President Barack Obama's 44th presidency, the World Trade Organization (WTO) conducted a Trade Policy Review (TPR) of the United States of America. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the "Trade Policy Review Body which is actually the WTO General Council — comprising the WTO’s full membership — operating under special rules and procedures" (Source: WTO, Trade Policy Reviews: Brief Introduction).
EB140: WHO adopts decision on terms of reference for overall programme review of the GSPOA (31 Jan 2017)Submitted by thiru on 31. January 2017 - 1:44
On 31 January 2017 the WHO Secretariat published the "Draft decision resulting from informal consultations" on the Overall programme review of the global strategy and plan of action on public health, innovation and intellectual property (EB140/CONF./7 Rev.1). This can be found here: http://apps.who.int/gb/ebwha/pdf_files/EB140/B140_CONF7Rev1-en.pdf
The chapeau to this decision notes:
EB140 heats up during discussions of proposed changes to resolution on TOR of Overall Programme Review of GSPOASubmitted by thiru on 28. January 2017 - 3:04
* (The author thanks the PHM Watchers for their notes of the WHO EB140 deliberations).
The Cámara de Diputados of the Chilean Congress voted on January 25, 2017 in favor of Resolution 798, calling on the government to implement compulsory licenses on drugs for cancer and other diseases. The vote was 67 yes, 0 no, and 32 abstentions. The resolution was put forward by Giorgio Jackson and six other members (V. Mirosevic, Miguel Alvarado, Karla Rubilar, Juan Luis Castro, Gabriel Boric, and Victor Torres).
EB140: Statement of India on the Report of the United Nations High-Level Panel on Access to MedicinesSubmitted by thiru on 23. January 2017 - 5:26
On the morning of Monday, 23 January 2017, India delivered the following intervention at the 140th session of the World Health Organization's Executive Board requesting the "explicit inclusion" of the United Nations Secretary-General's High-Level Panel Report in the "provisional agenda of the EB140 as a separate agenda item under item 8."
In making the case for the inclusion of the UN HLP in the WHO's Executive Board deliberations, India articulate the following:
Spinraza: KEI asks DHHS Office of the Inspector General (OIG) to investigate a failure to disclose federal funding in patentsSubmitted by James Love on 18. January 2017 - 13:41
KEI has asked the DHHS Office of Inspector General (OIG) to investigate a failure to disclose federal funding of patents on nusinersen, a drug developed by Ionis Pharmaceuticals (formerly known as Isis Pharmacetuicals) with BioGen, and sold under the trade name Spinraza.
A copy of the 22 page letter to OIG is available here.
At 11:06 P.M. on January 11, 2017, during the so-called “Vote-A-Rama”, the Senate considered an amendment put forward by Sen. Amy Klobuchar, D-Minn., and co-sponsored by Sen. Bernie Sanders, I-Vt., on the parallel importation of prescription drugs from Canada.
Groups Object to Army Proposal to Give Sanofi a Monopoly on Patents for Taxpayer-Funded Zika VaccineSubmitted by James Love on 12. January 2017 - 7:50
KNOWLEDGE ECOLOGY INTERNATIONAL
FOR IMMEDIATE RELEASE
12 JANUARY 2017
CONTACT: Zack Struver, firstname.lastname@example.org, +1 (202) 332-2670
Groups Object to Army Proposal to Give Sanofi a Monopoly on Patents for Taxpayer-Funded Zika Vaccine
KEI initial opposition to U.S. Army grant of exclusive license to Sanofi on patents for Zika virus vaccineSubmitted by KEI Staff on 21. December 2016 - 14:23
December 21, 2016 -- KEI has filed comments with the U.S. Army Medical Research and Materiel Command (USAMRMC) on the proposed grant of an exclusive license to Sanofi on patents on a vaccine for Zika Virus.
The Colombian Ministry of Health has finalized the price reduction of Glivec, Novartis's +$47 billion leukemia drug, with a decrease in price from 368 pesos per milligram to 206.42 pesos per mg.